A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma

ClinicalTrials.gov ID: NCT06736613

Public ClinicalTrials.gov record NCT06736613. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 2, 2026, 1:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Cerebral Spinal Fluid Circulating Tumor DNA (ctDNA) Analysis in Patients With Aggressive B-cell Lymphoma Receiving Front Line Therapy and at High Risk for Central Nervous System Relapse

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to find out how many people with B-cell lymphoma who are at high risk for central nervous system/CNS relapse test positive for cerebral spinal fluid/CSF ctDNA but test negative for CNS involvement using standard tests. The study will also look at how often CNS relapse happens in people with and without detected CSF ctDNA.

Study identification

NCT ID: NCT06736613
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Enrollment: 50 participants

Conditions and interventions

Conditions

Interventions

Cerebral Spinal Fluid ctDNA Diagnostic Test

Diagnostic Test

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 10, 2024
Primary completion: Dec 10, 2027
Completion: Dec 10, 2027
Last update posted: Dec 17, 2025

2024 – 2027

United States locations

U.S. sites: 7
U.S. states: 2
U.S. cities: 7

Facility	City	State	ZIP	Site status
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)	Basking Ridge	New Jersey	07920	Recruiting
Memorial Sloan Kettering Monmouth (Limited Protocol Activities)	Middletown	New Jersey	07748	Recruiting
Memorial Sloan Kettering Bergen (Limited Protocol Activities)	Montvale	New Jersey	07645	Recruiting
Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities)	Commack	New York	11725	Recruiting
Memorial Sloan Kettering Westchester (Limited Protocol Activities)	Harrison	New York	10604	Recruiting
Memorial Sloan Kettering Cancer Center (All Protocol Activites)	New York	New York	10065	Recruiting
Memorial Sloan Kettering Nassau (Limited Protocol Activities)	Rockville Centre	New York	11553	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06736613, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Dec 17, 2025 · Synced Sep 2, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06736613 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →